Etude : INCISIVE /



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme
Nom
Traitement
Type d'étude
MÀJ
Présentation de l'étude
Acronyme : INCISIVE

Nom :

Traitement :

Type d'étude : Qualité de vie / Observationnelle

Dernière MÀJ : 28/11/2019
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer (INCISIVE)

Spécialité : Organes digestifs
Localisation : C26 - Tumeur maligne des organes digestifs, de sièges autres et mal définis
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : With 42,150 new cases per year, colorectal cancer is the third cause of cancer in France according to the latest report from the Institut national du Cancer (INCa). Second leading cause of cancer death in men, its management is a public health problem. According to projections by WHO, the prevalence of cancers expected to increase 50% by 2050 especially in digestive oncology. These projections can be concluded that the demand for care will continue to be growing.

Medical advances and societal leading to increased life expectancy, have operated a mutation of the cancer disease. Formerly fatal disease, it is now a chronic disease in some cases. These changes are causing new challenges for the health system.

To address this problem, it is asked health professionals to adapt the organization of health care delivery to improve efficiency, in a constrained economic environment. To this end, action 4.1 of the cancer plan includes the creation of clinical nursing profession, a proposal reiterated in article 120 of the French Health System Law. Nursing clinicians will be empowered to ensure, under certain conditions, prescription treatments protocolized of follow-up tests, further treatment and support, as well as the extension or adaptation of specific treatments.

This project is a first step, in France, in thinking around new organizations in the supply of care in oncology.

For patients, strengthening their monitoring during chemotherapy, will better know their tolerance regarding chemotherapy. This optimized management of chemotherapy-induced effects will help reduce the use of emergency care.

The establishment of such a practitioner will free medical time to handle the most complex patients and perform tasks related to research.

For hospital pharmacies this type of organization will optimize their productivity by anticipating orders for chemotherapy pockets.

This project represents an opportunity to demonstrate the added value of advanced practice nurses in France in the health system and particularly in oncology. It also adds value to clinical expertise nurse and register the profession in the research.

The hypothesis is that the quality and safety of care provided by a nurse practitioner are equivalent to those provided by a doctor at follow-up of patients with gastrointestinal cancer, treated with intravenous chemotherapy.

Phase : NA

Stade : NA

NA
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : Digestive diagnostic of colorectal cancer.
Treatment with intravenous chemotherapy or treatment with concomitant oral and intravenous chemotherapy.
Patient beginning a cycle of chemotherapy he had already received chemotherapy sessions or not.
Patient aged 18 or over.
Patient with predictable life expectancy greater than 3 months.
Patient speak and understand the French.
Patient having read and understood the information letter and signed the consent form.
For women of childbearing age: effective contraception 3 months before the start of treatment and negative blood pregnancy test

Critères de non-inclusion : Patient aged over 80.
Patient aged under 18.
Prognosis committed within 3 months.
Pregnant women or breastfeeding.
Initial clinical assessment quoting fatigue to a higher grade 2 according to the WHO classification before the start of chemotherapy treatment.
Against indication(s) for chemotherapy.
Person deprived of liberty by an administrative or judicial decision or person under the protection of a conservator.
History of disease or psychological or sensory abnormality that may prevent the patient to understand the requirements for participation in the protocol or preventing it from giving informed consent.
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT02956876
Promoteur :
CHU de Rouen
Type de sponsor : Institutionnel
76000 ROUEN

Coordonnateur :
Pierre MICHEL
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
CHU de Rouen - 1 Rue de Germont - 76000 ROUEN

Investigateur :
Pr Pierre MICHEL

TEC / ARC / IDE :
Patricia FOSSE
patricia.fosse@
chu-rouen.fr

Ouverture de l'essai : OUVERT

MAJ : 28/11/2019